Ernexa Therapeutics Inc. 8-K

What Happened
Ernexa Therapeutics Inc. announced a 1-for-25 reverse stock split by filing a Certificate of Amendment to its Restated Certificate of Incorporation with the Delaware Secretary of State. The reverse split became effective at market open on May 4, 2026, and the company’s common stock began trading on a split-adjusted basis on Nasdaq that day. The new CUSIP for the post-split common stock is 114082407. The Certificate of Amendment is filed as Exhibit 3.1 to the company’s Form 8-K.

Key Details

• Reverse split ratio: 1-for-25.
• Effective date: market open, May 4, 2026; Nasdaq trading adjusted that day.
• New CUSIP: 114082407.
• Certificate of Amendment filed as Exhibit 3.1 to the 8-K.

Why It Matters
A 1-for-25 reverse split consolidates every 25 pre-split shares into one post-split share and proportionally increases the per-share price while reducing the number of outstanding shares. For investors, this means brokerage accounts and share counts will be adjusted to reflect the new ratio and the stock will trade at split-adjusted prices going forward. The filing does not state any other corporate actions or provide reasons for the reverse split. Investors should check their account statements and brokerage notifications for updated share totals and pricing.